ASH 2021 | Cilta-cel vs. therapies from real-world clinical practice for triple-class exposed myeloma
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses the results of a study comparing outcomes of patients with triple-class exposed multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel) versus therapies from real-world clinical practice. The safety and efficacy of cilta-cel was assessed in this population in the CARTITUDE-1 single arm Phase Ib/II clinical trial (NCT03548207). Given the lack of comparator group in CARTITUDE-1, comparing outcomes from the trial to those of patients treated in real-world clinical practice could provide valuable insights on the optimal treatment options for triple-class exposed myeloma. Almost 250 patients from the LocoMMotion prospective cohort were included in the study. Over 90 different regimens were used, most commonly carfilzomib-dexamethasone, pomalidomide–cyclophosphamide–dexamethasone and pomalidomide–dexamethasone. The comparison revealed that treatment with cilta-cel compared to real-world regimens resulted in statistically significant improvements in overall response rate, progression-free survival, and overall survival, highlighting the potential of cilta-cel as an effective option for these patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
The idea was, and that was actually mainly done in Europe because at that time, we were not able really, at least for a lot of patients to get hold of cilta-cel, to compare patients that would potentially qualify for the cilta-cel study, the CARTITUDE-1 study and see how these patients would perform when receiving standard of care therapy.
And looking at this comparison, it was very clear that the CAR-T cell therapy was much more effective and obviously even less toxic than a lot of the other standard of care combinations that were used for the patients in this comparative trial...
The idea was, and that was actually mainly done in Europe because at that time, we were not able really, at least for a lot of patients to get hold of cilta-cel, to compare patients that would potentially qualify for the cilta-cel study, the CARTITUDE-1 study and see how these patients would perform when receiving standard of care therapy.
And looking at this comparison, it was very clear that the CAR-T cell therapy was much more effective and obviously even less toxic than a lot of the other standard of care combinations that were used for the patients in this comparative trial.
So in summary, the BCMA directed CAR-T cell product cilta-cel was clearly superior to any chosen standard of care therapy for patients with advanced relapsed/refractory multiple myeloma.
Read more...
